Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL57126 | 1.00 | TDP1 (0.53) | TDP1L3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL9021326 | 1.00 | TDP1 (0.53) | TDP1L3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL73699 | 1.00 | TDP1 (0.53) | TDP1L3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL9021214 | 1.00 | TDP1 (0.53) | TDP1L3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL9021262 | 1.00 | TDP1 (0.53) | TDP1L3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL9021124 | 1.00 | TDP1 (0.53) | TDP1L3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL8500469 | 1.00 | TDP1 (0.53) | TDP1L3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL8496728 | 1.00 | TDP1 (0.53) | TDP1L3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL9022098 | 1.00 | TDP1 (0.53) | TDP1L3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL8498166 | 1.00 | TDP1 (0.53) | TDP1L3MBTL1MEN1KMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2644599-B1 | Method for preparing a 2-halo-4-nitroimidazole compound | OTSUKA PHARMA CO LTD (JP) | 2014-12-10 | — | — | EP | disclosed |
| EP-2528896-B1 | SYNTHETIC INTERMEDIATE OF OXAZOLE COMPOUND AND METHOD FOR PRODUCING THE SAME | OTSUKA PHARMA CO LTD (JP) | 2014-08-27 | — | — | EP | disclosed |
| US-8598358-B2 | Synthetic intermediate of oxazole compound and method for producing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-12-03 | — | — | US | disclosed |
| US-8552188-B2 | Epoxy compound and method for manufacturing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-2644599-A1 | Method for preparing 1-substituted-4-nitroimidazole compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-02 | — | — | EP | disclosed |
| US-20130072683-A1 | EPOXY COMPOUND AND METHOD FOR MANUFACTURING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-21 | — | — | US | disclosed |
| US-8344148-B2 | Epoxy compound and method for manufacturing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-01 | — | — | US | disclosed |
| EP-2528896-A1 | SYNTHETIC INTERMEDIATE OF OXAZOLE COMPOUND AND METHOD FOR PRODUCING THE SAME | Otsuka Pharmaceutical Co., Ltd. (JP) | 2012-12-05 | — | — | EP | disclosed |
| US-20120302757-A1 | SYNTHETIC INTERMEDIATE OF OXAZOLE COMPOUND AND METHOD FOR PRODUCING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-11-29 | — | — | US | disclosed |
| US-20120130082-A1 | 1-Substituted-4-Nitroimidazole Compound and Method for Preparing the Same | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-05-24 | — | — | US | disclosed |
| US-20080097107-A1 | 1-substituted-4-nitroimidazole compound and method for preparing the same | OTSUKA PHARMACEUTICAL CO. LTD. | 2008-04-24 | — | — | US | disclosed |
| US-20060079697-A1 | 1-substituted-4-nitroimidazole compound and process for producing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-04-13 | — | — | US | disclosed |
| EP-1553088-A1 | 1-SUBSTITUTED 4-NITROIMIDAZOLE COMPOUND AND PROCESS FOR PRODUCING THE SAME | Otsuka Pharmaceutical Company, Limited (JP) | 2005-07-13 | — | — | EP | disclosed |
| US-5607934-A | PREVENTING AND TREATING DISEASES CAUSED BY SUPEROXIDE RADICALS, NEPHRITIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-03-04 | — | — | US | disclosed |
| EP-0500853-B1 | PHENYLETHANOLAMINES, DRUGS CONTAINING THESE COMPOUNDS, AND A METHOD OF PREPARING THEM | THOMAE GMBH DR K (DE) | 1996-12-27 | — | — | EP | disclosed |
| EP-0659182-A1 | PIPERAZINE DERIVATIVES AND SALTS THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-06-28 | — | — | EP | disclosed |
| US-5393774-A | Antispasmodic agents | PIEPER HELMUT (DE) | 1995-02-28 | — | — | US | disclosed |
| WO-1995002593-A1 | PIPERAZINE DERIVATIVES AND SALTS THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-01-26 | — | — | WO | disclosed |
| EP-0500853-A1 | PHENYLETHANOLAMINES, DRUGS CONTAINING THESE COMPOUNDS, AND A METHOD OF PREPARING THEM. | THOMAE GMBH DR K (DE) | 1992-09-02 | — | — | EP | disclosed |
| WO-1992004316-A1 | PHENYLETHANOLAMINES, DRUGS CONTAINING THESE COMPOUNDS, AND A METHOD OF PREPARING THEM | DR. KARL THOMAE GMBH (DE) | 1992-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130082-A1 | 1-Substituted-4-Nitroimidazole Compound and Method for Preparing the Same | CBR1, CBR3, DCXR | TDP1 3348/4885L3MBTL1 3949/4885MEN1 2625/4885 |
| US-20060079697-A1 | 1-substituted-4-nitroimidazole compound and process for producing the same | CBR1, CBR3, DCXR | TDP1 3453/4885L3MBTL1 3860/4885MEN1 3073/4885 |
| US-20120302757-A1 | SYNTHETIC INTERMEDIATE OF OXAZOLE COMPOUND AND METHOD FOR PRODUCING THE SAME | GLP1R, HBB, OXA1L | TDP1 3602/4885L3MBTL1 926/4885MEN1 2563/4885 |
| US-20130072683-A1 | EPOXY COMPOUND AND METHOD FOR MANUFACTURING THE SAME | SQLE, CYP2E1, CYP1A1 | TDP1 4195/4885L3MBTL1 1803/4885MEN1 2367/4885 |
| US-20080097107-A1 | 1-substituted-4-nitroimidazole compound and method for preparing the same | CBR1, CBR3, DCXR | TDP1 3348/4885L3MBTL1 3949/4885MEN1 2625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.